Open AccessHyperthermic Intraperitoneal Chemotherapy as a Treatment for Epithelial Ovarian Cancer
Author(s) -
Mohamed Ibrahim Fahim,
Omaya Nassar,
O. Mansour,
Abdelmaksoud Mohamed Ali,
Ahmed-Mostafa Mahmoud,
Nesreen H. Hafez,
Rasha Mahmoud Allam,
Amr Kamal,
Mohamed Ghareeb
Publication year - 2019
Publication title -
indian journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.231
H-Index - 16
eISSN - 0976-6952
pISSN - 0975-7651
DOI - 10.1007/s13193-018-0867-y
Subject(s) - surgical oncology , medicine , intraperitoneal chemotherapy , epithelial ovarian cancer , ovarian cancer , chemotherapy , oncology , hyperthermic intraperitoneal chemotherapy , general surgery , cancer , cytoreductive surgery
Treatment by cytoreductive surgery (CRS) and intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) has been an option for selected patients with peritoneal carcinomatosis. This study aims to evaluate the impact of HIPEC in epithelial ovarian cancer (EOC). A retrospective observational cohort study including 48 EOC patients treated and followed up between 2012 and 2016. Thirty-seven cases were treated by CRS only, while 11 cases were treated by CRS and HIPEC. The study was performed at National Cancer Institute (NCI)-Cairo University. There was no statistically significant difference regarding overall survival or disease-free survival between the group of EOC patients treated by CRS only and the one treated by CRS and HIPEC. Presence of ascites and histological types (serous/non-serous) were the significant independent variables related to overall survival. Presence of ascites was the only independent variable associated with a significant relation to disease-free survival. No statistically significant impact of HIPEC in treatment of EOC was found in this study.